Connect with us

Updates for the Multidisciplinary Oncology Care Team on the Biology, Clinical Data, and Safety of HER3-Targeted Agents in Lung Cancer

Webinar/Online

Tuesday, December 3, 2024 at 7:00pm CT - 8:00pm CT
This event has ended.

CME

Info

Topic

Lung Cancer

Credits Offered

This event offers 1.0 CME credit to attendees.
Accreditation Info: Accreditation Council for Continuing Medical Education.

Additional Information

Learning objectives:

  • Appraise the biologic and clinical relevance of HER3 in advanced NSCLC and EGFR- resistant NSCLC.
  • Summarize the clinical trial data and design of ongoing trials with HER3-targeted antibodies in the management of NSCLC.
  • Evaluate the relevance of members of the multidisciplinary team in adverse event monitoring and management with HER3-directed therapies

Speakers

Shayma Kazmi
Shayma Kazmi MD

Dr. Shayma Kazmi is a Medical Oncologist and Hematologist at Penn Abramson Cancer Center, University of Pennsylvania. She also serves as an Assistant Professor of Medicine at Rowan School of Medicine in Stratford, NJ.

Event Agenda

Updates for the Multidisciplinary Oncology Care Team on the Biology, Clinical Data, and Safety of HER3-Targeted Agents in Lung Cancer

Event Agenda

Tuesday, December 3, 2024 at 7:00pm CT - 8:00pm CT

All times listed in Central Time (US & Canada).
Download event agenda (PDF)

Tuesday, December 3, 2024

  • 7:00pm - 8:00pm

    Updates for the Multidisciplinary Oncology Care Team on the Biology, Clinical Data, and Safety of HER3-Targeted Agents in Lung Cancer

    Shayma Kazmi, MD
    1.0 CE Credit

    Learning Objectives:
    - Appraise the biologic and clinical relevance of HER3 in advanced NSCLC and EGFR- resistant NSCLC.
    - Summarize the clinical trial data and design of ongoing trials with HER3-targeted antibodies in the management of NSCLC.
    - Evaluate the relevance of members of the multidisciplinary team in adverse event monitoring and management with HER3-directed therapies